Al Jedai A1, AL-Mudaiheem H1, Haines A2, Mosli M3, Albogami M4, Al-jaroudi F5, Alsaqa'aby M6, Awad N7, Mohamed O8
1Ministry of Health, Riyadh, NJ, Saudi Arabia, 2Toronto University, Toronto, ON, Canada, 3King Abdulaziz University, Jeddah, Saudi Arabia, 4Ministry of Health, Damam, Saudi Arabia, 5King Fahad Specialist Hospital, Damam, Saudi Arabia, 6King Faisal Specialized Hospital and Research Center, Riyadh, Saudi Arabia, 7IQVIA, Dubai, United Arab Emirates, 8IQVIA, Dubai, NJ, Saudi Arabia


Inflammatory bowel disease (IBD) is a complex group of diseases including ulcerative colitis (UC) and Crohn’s disease (CD). In Kingdom of Saudi Arabia (KSA), the prevalence of UC and CD were 0.24% and 0.2%, respectively. The Ministry of Health (MOH) conducted a class review of all biologics used for IBD management. This study assessed the current total cost of UC and CD management using Adalimumab, infliximab and Ustekinumab (UC only) in patients who failed to respond to conventional therapy and the budgetary impact of including Vedolizumab and/or Certolizumab for the management of CD and Vedolizumab and/or Golimumab for the management of UC.

METHODS : An excel based model was developed to assess two scenarios: “Current Scenario“ where UC and CD were managed using Adalimumab, Infliximab and/or Ustekinumab and “Alternative Scenarios” where UC and CD were managed using the current drugs in addition to Vedolizumab, Golimumab and/or Certolizumab. The model considered direct health costs such as drug acquisition, drug administration, adverse events management, healthcare resources utilization across different responses, and probabilities of dose escalation. The model inputs were retrieved from literature whenever available and validated by key experts through face-to-face interviews. The market shares of new drugs were varied based on experts’ insights on drugs positioning and plausible uptake scenarios. The total market shares of the new drugs, individually or combined, ranged from 0% to 25% in UC and from 0% to 11% in CD


In MOH, the current total costs of UC and CD management over 5 years were SAR 235.9 million and 430.6 million; respectively. The uptake of any of the drugs, resulted in 1% to 2.2% increase in the total budget of IBD management over 5 years.


The adoption of one or more new biologics would minimally increase the total cost of IBD management

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark




Biologics and Biosimilars, Gastrointestinal Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now